Roche chemo-immunotherapy combo mets NSCLC Phase III endpoint – European Biotechnology
European Biotechnology |
Roche chemo-immunotherapy combo mets NSCLC Phase III endpoint
European Biotechnology A Phase III study (IMpower150) sponsored by Roche has shown that a combo of the company's PD-L1 blocker atezolizumab (Tecentriq) and VEGF blocking antibody bevacizumab (Avastin) plus paclitaxel + carboplatin vs Avastim plus chemotherapy … Roche announces trial successes in cancer, haemophilia UPDATE 3-Roche shares climb after trial wins in cancer, haemophilia |
